NCCN Tumor Boards: Managing Unique Toxicities and IRAs in Hodgkin Lymphoma
NCCN will host a specialized tumor board session titled “Managing Unique Toxicities and Immune-Related Adverse Effects of Treatment for Hodgkin Lymphoma” on April 30, 2026, from 3:00 PM to 4:00 PM EDT.
As the treatment paradigm for advanced classic Hodgkin lymphoma (cHL) shifts toward frontline antibody-drug conjugates and immune checkpoint inhibitors, clinicians must pivot from managing traditional chemotherapy risks to addressing novel side effects. This activity will provide oncology professionals with practical strategies for navigating unique toxicities, including brentuximab vedotin-associated peripheral neuropathy and immune-related adverse effects, while reviewing key data from the SWOG S1826, ECHELON-1, and GHSG HD21 trials to optimize modern patient care.